Loading clinical trials...
Loading clinical trials...
A Phase 2 Open Label, Single Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel as Neoadjuvant Therapy in Patients Undergoing Surgical Resection of Squamous Cell Carcinoma (SCC)
Conditions
Interventions
Remetinostat
Locations
1
United States
Stanford Medical Center
Stanford, California, United States
Start Date
December 12, 2019
Primary Completion Date
May 14, 2020
Completion Date
January 30, 2021
Last Updated
May 20, 2021
NCT07463573
NCT05268614
NCT06532279
NCT06563479
NCT07209189
NCT06731933
Lead Sponsor
Kavita Sarin
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions